

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sarah S. Bacus et al.

Serial No.: 10/600,129

Group Art Unit No.: 1643

Filed: June 19, 2003

Examiner: Anne L. Holleran

For: Method for Predicting Response to Epidermal Growth
Factor Receptor-Directed Therapy

Confirmation No.: 9778

Docket No.: 6155-US-NP

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the reference(s) submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of the reference(s).

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

A ☐ a statement as specified in 37 CFR 1.97(e):

STATEMENT

CERTIFICATE OF ELECTRONIC SUBMISSION

I hereby certify that this paper is being electronically transmitted to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date appearing below.

June 22, 2009
Date

Lynne Buchsbaum
Signature

PATENT APPLICATION

I, the person(s) signing below state:

- ☐ that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).

OR

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).

OR


- B. ☒ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,



Scott N. Bernstein
Attorney/Agent for Applicant(s)
Registration No.: 38,827
Phone: (805) 447-4128
Date: June 11, 2009.

Please send all future correspondence to:
US Patent Operations/SNB
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799